News

AVTR expands its RIM single-use bioprocessing portfolio across APAC, boosting access to locally made solutions and supporting its bioprocessing growth push.

West Pharmaceutical's biologics exposure, Annex 1 projects and delivery-device growth support prospects despite near-term headwinds.

SOLV's strong Q2 performance, growth investments and cost-saving program support its outlook, though higher raw material costs remain a concern.

AVTR's strong Q2 results, improving orders and raised 2026 outlook support growth prospects, though BMP weakness and uneven demand remain concerns.

BTSG's specialty pharmacy, infusion and home-based care expansion support growth, while IRA and execution risks may put pressure on near-term margins.

BD expands U.S. pharmacy automation with Vmax 160 at Fairview to handle complex specialty and refrigerated medications.

Intuitive Surgical's da Vinci meta-analysis across 14 million procedures found better perioperative outcomes versus laparoscopic and open surgery.

DXCM's strong growth, G7 15 Day adoption and CONNECT trial could expand its CGM market opportunity despite reimbursement and competition risks.

Bausch + Lomb gains European CE Mark approval for SeeLyra, expanding its surgical portfolio with a compact laser platform for cataract and corneal procedures.

RVTY's HCD deal is expected to add human pancreatic beta cell models, expanding drug discovery and preclinical research tools for metabolic diseases.

ICCM's NMPA approval for ProSense opens China to commercialization, expanding its global regulatory footprint and long-term revenue opportunity.

ECL benefits from high-tech growth, digital expansion, innovation and solid Q2 results, while cost fluctuations remain a key concern.

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.

DVA gains from expanding value-based kidney care, improving dialysis volumes and clinical innovation, though payer-mix and regulatory risks persist.

GEHC moves StarGuide GX closer to the U.S. market with an FDA 510(k) submission, advancing its next-generation molecular imaging push.

COO Q3 earnings are likely to benefit from CooperVision strength, improving fertility trends and efficiency gains offsetting Asia-Pacific pressure.

PACS plans to acquire operations of 32 Florida skilled nursing facilities, adding 4,049 licensed beds and establishing a statewide network.

AMN Healthcare is poised for growth as staffing demand rebounds, MSP penetration expands and tech-enabled workforce solutions broaden its reach.

NYXH initiates its U.S. BREATHE study with the first Genio implant, advancing long-term clinical evidence following FDA approval.

PHG broadens women's health ultrasound portfolio with the eV14-2v, offering enhanced imaging, a lighter design and remote collaboration.

NVCR says a cyber incident exposed limited patient and contact data, but devices stayed secure and operations remained fully functional.

Generation Investment Management, an investment management firm, released its “Global Equity Strategy” second quarter 2026 investor letter. The letter can be downloaded here. The letter discusses the challenges of AI-driven market concentration and emphasizes the potential for long-term investors. It notes that the best companies are currently underperforming due to market returns being concentrated in […]

How West Pharmaceutical Services stock has been performing West Pharmaceutical Services (WST) has drawn investor attention after recent share price moves, with the stock closing at US$339.97 on 3 September 2026. The company shows mixed returns over different periods, including gains over the past year alongside shorter term pullbacks. For West Pharmaceutical Services, the recent 1-day share price decline of 0.81% and 3.15% share price pullback over 30 days sit against a much stronger...

Cencora's specialty momentum, OneOncology growth and GLP-1 volumes offer upside, but drug-price cuts and MWI risks cloud its outlook.

HQY's growth is driven by rising HSA assets and AI-led efficiencies, while cybersecurity risks remain a key concern.

PHG's AI-powered 3D Auto CFQ shows stronger agreement with cardiac MRI than 2D PISA, supporting its cardiovascular ultrasound strategy.

NPCE's RNS adoption, reimbursement gains, referral expansion and AI tools support growth, while IGE delays and higher spending pressure profitability.

COR launches CGT Enablement to help health systems build and scale cell and gene therapy programs with financial, operational and access support.

VEEV's strong Q2 results, Vault CRM migrations and AI expansion support growth, while market saturation remains a key concern.

SYK's FDA-cleared SportSuite Vision brings Apple Vision Pro into hip arthroscopy, strengthening its digital surgery push and Sports Medicine portfolio.